Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | TRPM5 | Q9NZQ8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21646345 | 0.80 | EGFR (0.36) | TRPM5 | |
| SCHEMBL24783498 | 0.75 | PIK3CD (0.35) | TRPM8ABL1TDP1 | |
| SCHEMBL23055243 | 0.72 | TRPM5 (0.47) | TRPM8ABL1TDP1TRPM5 | |
| SCHEMBL21646376 | 0.69 | TDP1 (0.31) | TRPM8TDP1TRPM5 | |
| SCHEMBL21646370 | 0.69 | ABL1 (0.38) | TRPM8ABL1TDP1TRPM5 | |
| SCHEMBL23697853 | 0.68 | ABL1 (0.34) | ABL1TDP1 | |
| SCHEMBL22001245 | 0.68 | ROCK2 (0.38) | ABL1TDP1 | |
| SCHEMBL23432578 | 0.67 | ABL1 (0.34) | ABL1TDP1 | |
| SCHEMBL12890527 | 0.67 | NPSR1 (0.53) | — | |
| SCHEMBL21477560 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230109839-A1 | THERAPEUTIC AGENT FOR TAUOPATHIES | Sumitomo Pharma Co., Ltd. (JP) | 2023-04-13 | — | — | US | disclosed |
| WO-2021039961-A1 | RING-FUSED PYRAZOLE DERIVATIVE | 大日本住友製薬株式会社 | 2021-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230109839-A1 | THERAPEUTIC AGENT FOR TAUOPATHIES | MAPT, PSEN1, PSEN2 | TRPM8 25/4885ABL1 3883/4885TDP1 614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.